Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Adding N-Acetylcysteine to Gabapentin on Itching and Sleep Quality in Patients Undergoing Hemodialysis
IRCT20260721070277N1Phase 3Not yet recruiting
- Sponsor
- Dezful University of Medical Sciences
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetylcysteine and gabapentin in chronic kidney disease-associated pruritus (CKD-aP), sleep disorder and end-stage kidney disease (ESKD) (2 arms), sponsored by Dezful University of Medical Sciences. Primary endpoints: Change in itching severity and Change in sleep quality. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
acetylcysteinegabapentin
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)sleep disorderend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20260721070277N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260721070277N1.